Endogenous Ceramide 24:1 Constrains Th17-Driven Neutrophilic Inflammation by Antagonizing EP2 Signaling - PubMed
7 hours ago
- #ceramide
- #neutrophilic asthma
- #Th17 cells
- Ceramide 24:1 (Cer24:1) deficiency is linked to neutrophilic asthma (NA) severity and Th17-driven inflammation.
- Cer24:1 supplementation reduces airway hyperresponsiveness and neutrophilic infiltration in vivo.
- Cer24:1 directly targets the prostaglandin E2 receptor EP2 on CD4+ T cells, suppressing Th17 differentiation via JAK2-STAT3 signaling.
- PGE2 competitively reverses Cer24:1's protective effects, confirming EP2-dependent modulation.
- Cer24:1 acts as an endogenous pro-resolving lipid, offering a potential therapeutic strategy for severe neutrophilic asthma.